This Hedge Fund Has Made a Fortune on Hepatitis C Companies

0
This Hedge Fund Has Made a Fortune on Hepatitis C Companies

One hedge fund is on a winning streak when it comes to takeovers of companies developing hepatitis C treatments.

Play Quizzes 4

QVT Financial, started by ex-Deutsche Bank prop traders, is among the largest shareholders of Inhibitex, which agreed over the weekend to a $2.5 billion acquisition by Bristol-Myers Squibb.

According to regulatory filings, QVT first bought shares for about $1 each in 2009, and also took warrants to acquire millions more shares at $1.46 each. That means QVT’s stock is worth about $105 million at Bristol-Myers’s takeover price, or very roughly 25 times what QVT paid for its investment in 2009.

Fund Manager Profile: Zhang Hui Of China’s Southern Asset Management

investHistorically, the Chinese market has been relatively isolated from international investors, but much is changing there now, making China virtually impossible for the diversified investor to ignore. Earlier this year, CNBC pointed to signs that Chinese regulators may start easing up on their scrutiny of companies after months of clamping down on tech firms. That Read More

http://blogs.wsj.com/deals/2012/01/09/this-hedge-fund-has-made-a-fortune-on-hepatitis-c-companies/?mod=WSJBlog

ValueWalk Premium Subscription Includes:
  • 3 Write-ups per month (EXCLUSIVE content that you won’t find anywhere else)
  • Personal Track Record from Jacob’s Brokerage
  • Any question you have answered within 48 hours
This Hedge Fund Has Made a Fortune on Hepatitis C Companies

 

 

Updated on

No posts to display